Data / Form D filings / Accipiter Biosciences Inc.
Accipiter Biosciences Inc.: Form D filings
Accipiter Biosciences Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2023 and 2026. The latest, on July 28, 2026, reports $10.5 million sold of a $10.5 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1616 EASTLAKE AVE E. SUITE 208, Seattle, WA, 98102
- Phone
- (212) 472-6343
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1973963
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | New notice | $10,492,778 | $10,492,778 | 9 | Jul 21, 2026 | sec.gov | |
| Sep 24, 2025 | Amendment | $13,690,000 | $13,598,492 | $91,508 | 15 | May 17, 2024 | sec.gov |
| May 28, 2024 | New notice | $13,690,000 | $7,919,997 | $5,770,003 | 13 | May 17, 2024 | sec.gov |
| May 2, 2023 | New notice | $1,000,000 | $650,000 | $350,000 | 6 | Apr 19, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Bick | Executive Officer, Director, Promoter | |
| Hector De Jesus Rincon Arano | Executive Officer, Director, Promoter | |
| Javier Castellanos | Executive Officer, Director, Promoter | |
| Heather Redman | Director | |
| Randall Schatzman | Director | |
| William Canestaro | Executive Officer | |
| Jose Antonio Mesa Cejudo | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Jul 27, 2026 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Accipiter Biosciences Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.